Why is Boston Scientific stock sliding today?
Boston Scientific (BSX) shares fell 3.6% to $43.42 in pre-market trading after reporting Q3 2026 earnings. Adjusted EPS of $0.73 missed estimates by $0.02, while revenue of $5.14B exceeded expectations. The company cut Q4 and full-year 2026 EPS guidance due to a cyberattack and other challenges, citing a 1%-3% expected decline in Q4 sales.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to trigger short‑term selling pressure, especially given the recent cyber‑attack disruption.
Market read
The earnings surprise and guidance downgrade are primary catalysts for a near‑term price decline.
What to watch
Potential upside from upcoming product launches or cost‑saving initiatives not reflected in the guidance.
Background
Boston Scientific's Q3 results were released before the bell, highlighting a modest revenue beat but a miss on EPS and a significant guidance reduction.
Ticker impact
Boston Scientific reported Q3 2026 earnings miss and cut full-year guidance, causing a 3.6% pre‑market slide.
likely further decline as investors price in weaker earnings and guidance
Adjusted EPS fell short of consensus and full‑year EPS guidance was trimmed, a material catalyst for short‑term sell pressure.
Market effects
Medical device sector may face broader scrutiny as guidance cuts signal slower demand.
U.S. healthcare stocks could see modest weakness in early trade.
Limited; impact confined mainly to U.S. equities.
Counterpoint
If the cyber‑attack impact eases faster than expected, the stock could rebound on a valuation discount.
Key entities
- CompanyBoston Scientific
Medical device maker reporting Q3 2026 earnings.
